Skip to main content
Zealand Pharma logo

Zealand Pharma — Investor Relations & Filings

Ticker · ZEAL ISIN · DK0060257814 LEI · 549300ITBB1ULBL4CZ12 CO Professional, scientific and technical activities
Open in API
Filings indexed 1,525 across all filing types
Latest filing 2026-05-14 Regulatory Filings
Country DK Denmark
Listing CO ZEAL

About Zealand Pharma

https://www.zealandpharma.com/

Zealand Pharma is a biotechnology company specializing in the discovery, design, and development of innovative peptide-based medicines. The company's primary focus is on advancing treatments for obesity and metabolic diseases, with a strategic goal to become a leader in this field. Its pipeline includes multiple candidates targeting obesity, such as petrelintide (a long-acting amylin analog) and survodutide (a glucagon/GLP-1 dual agonist licensed to a partner). Beyond metabolic health, Zealand Pharma develops therapies for rare diseases, including dasiglucagon for congenital hyperinsulinism and glepaglutide for short bowel syndrome. The company also has programs in chronic inflammation. Leveraging its expertise in peptide science, the company aims to create next-generation therapeutics to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
Zealand Pharma - Transactions related to share buy-back program (weeks 19-20, 2026)
Regulatory Filings
2026-05-14 Danish
Zealand Pharma - Transactions related to share buy-back program (weeks 19-20, 2026)
Transaction in Own Shares Classification · 92% confidence The document is a company announcement detailing the execution of transactions under its share buy-back program, including dates, share quantities, prices, and cumulative totals. It references the Market Abuse Regulation and provides a breakdown of treasury shares held post-transactions. This matches the definition for “Transaction in Own Shares” (POS), which covers reports of share repurchase activities.
2026-05-14 English
Zealand Pharma - Execution framework for share buy-back program
Regulatory Filings
2026-05-07 Danish
Zealand Pharma initiates USD 200 million / DKK 1.3 billion share buy-back program
Regulatory Filings
2026-05-07 Danish
Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management
Regulatory Filings Classification · 55% confidence The document is a company announcement/press release regarding the advancement of a drug candidate into Phase 3 trials. It contains forward‐looking statements and operational pipeline news but no financial results, no meeting materials, no regulatory form citations, nor detailed financial tables or management discussion. It does not fit any specific category such as earnings release, call transcript, M&A, or annual/interim report. As a general press release update, it defaults to the fallback “Regulatory Filings” category (RNS).
2026-04-29 English
Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesi
Regulatory Filings Classification · 85% confidence The document is a press‐style corporate announcement disclosing Phase III clinical trial topline results for a drug candidate. It does not present financial results (earnings or interim), a full annual/interim report, management changes, capital activity, or any other specialized category. It is essentially a general corporate/regulatory disclosure, so the appropriate classification is the fallback “Regulatory Filings” (RNS).
2026-04-28 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.